Skip to main content

Table 1 PAF levels and metabolic enzymes of ART groups

From: In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients

Parameter

Groups

Baseline/0 month

1stmonth

3rdmonth

6thmonth

9thmonth

12thmonth

ptime

Pint.

Bound PAF (fmol/mL)

T

1.66

1.11*

0.90*

1.08*

1.12

0.74*

0.010

0.357

(1.35-2.02)

(0.70-1.18)

(0.70-1.30)

(0.70-1.54)

(0.70-2.11)

(0.70-1.18)

A

0.90

1.10

5.54*

1.42

1.14

1.53

0.028

P 3 = 0.038

(0.70-6.20)

(0.70-2.41)

(0.97-17.29)

(0.78-3.85)

(0.93-1.71)

(0.78-2.39)

P 12 = 0.083

PAF-CPT in HLs (pmol/min/mg)

T

546.50

336.00*

191.50*

232.00*

338.50*

288.50*

0.009

0.304

(416.50-730.25)

(182.50-451.75)

(114.50-518.00)

(147.25-461.25)

(231.25 -381.25)

(236.50-341.75)

A

344.50

257.00

438.00

344.00

495.00

445.00*

0.085

(215.25-787.75)

(221.75-515.25)

(183.00-535.50)

(173.50-795.50)

(252.50-755.00)

(330.00-920.00)

Lyso-PAF-AT in HLs (pmol/min/mg)

T

22.95

12.40

12.20

8.40*

13.85*

16.40*

0.002

0.818

(11.90-26.65)

(10.75-33.27)

(8.02-28.07)

(2.22-12.92)

(8.47-17.60)

(9.77-19.75)

A

9.15

10.75

20.60*

10.55

13.50

12.50

0.141

(6.12-19.82)

(5.25-22.20)

(7.42-35.75)

(6.85-27.27)

(8.00-27.75)

(6.50-24.25)

PAF-AH in HLs (pmol/min/mg)

T

69.17

55.68

70.71

54.18*

46.32*

45.81*

0.002

0.732

(42.94-106.97)

(32.34-80.52)

(37.47-114.14)

(33.09-65.45)

(28.23-62.67)

(25.79-51.56)

A

50.54

52.68

64.03*

61.30

57.05

52.24

0.180

(46.57-58.78)

(34.37-72.78)

(50.80-92.62)

(32.55-75.06)

(36.49-66.05)

(40.54-61.08)

Lp-PLA2 (pmol/min/μL)

T

29.35

26.15

34.20

29.10

26.40*

27.15*

0.003

0.017

(24.40-34.12)

(23.70-35.37)

(30.00-35.12)

(26.15-38.47)

(22.44-29.35)

(20.79-28.50)

A

33.66

32.63

33.59

33.67

37.55*

33.33

0.002

P 3 = 0.038

(30.30-35.89)

(27.20-36.59)

(29.32-38.15)

(27.61-35.48)

(35.67-42.43)

(31.63-40.90)

P 12 = 0.083

  1. Group_T: tenofovir-DF/emtricitabine/ efavirenz and Group_A: abacavir/lamivudine/ efavirenz. All the results are expressed as median values and interquartile range (25th-75th). HLs: Human Leukocytes. ptime displays the difference within the group during the overall 12-month treatment.
  2. *: displays the significant difference of each time point with the baseline value (p < 0.05).
  3. Pint displays the difference between the two groups during the overall 12-month treatment.
  4. Pspecific-time-point displays the significant difference between the two groups at a specific time point.